Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$78.25
+0.3%
$66.44
$21.74
$80.39
$1.34B1.65167,567 shs31,716 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.75
0.0%
$14.48
$5.30
$19.11
$1.16B1.761.21 million shs443,217 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.90
+1.4%
$2.90
$0.62
$4.31
$368.53M0.75277,969 shs60,196 shs
Transcat, Inc. stock logo
TRNS
Transcat
$77.61
+3.0%
$76.20
$50.23
$97.08
$724.07M0.68140,867 shs62,414 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
+2.25%+4.94%+28.84%+26.44%+258.79%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+3.07%+2.08%+2.61%+11.52%+100.44%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
+5.93%+10.42%-13.60%+37.50%+317.40%
Transcat, Inc. stock logo
TRNS
Transcat
+3.89%-0.46%-1.14%+6.64%-5.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$78.25
+0.3%
$66.44
$21.74
$80.39
$1.34B1.65167,567 shs31,716 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.75
0.0%
$14.48
$5.30
$19.11
$1.16B1.761.21 million shs443,217 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.90
+1.4%
$2.90
$0.62
$4.31
$368.53M0.75277,969 shs60,196 shs
Transcat, Inc. stock logo
TRNS
Transcat
$77.61
+3.0%
$76.20
$50.23
$97.08
$724.07M0.68140,867 shs62,414 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
+2.25%+4.94%+28.84%+26.44%+258.79%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+3.07%+2.08%+2.61%+11.52%+100.44%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
+5.93%+10.42%-13.60%+37.50%+317.40%
Transcat, Inc. stock logo
TRNS
Transcat
+3.89%-0.46%-1.14%+6.64%-5.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allient Inc. stock logo
ALNT
Allient
2.50
Moderate Buy$70.75-9.58% Downside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$32.20134.22% Upside
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
2.00
Hold$4.0037.93% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.40
Hold$105.3335.73% Upside

Current Analyst Ratings Breakdown

Latest NAUT, ALNT, EYPT, and TRNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Transcat, Inc. stock logo
TRNS
Transcat
Reiterated RatingSell (D)
4/21/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingSell (D-)
4/21/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Reiterated RatingSell (D-)
4/6/2026
Transcat, Inc. stock logo
TRNS
Transcat
DowngradeHoldStrong Sell
3/16/2026
Allient Inc. stock logo
ALNT
Allient
Boost Price TargetBuy$56.00 ➝ $69.00
3/9/2026
Allient Inc. stock logo
ALNT
Allient
Reiterated RatingBuy$75.00
3/9/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Boost Price TargetBuy$31.00 ➝ $35.00
3/5/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Boost Price TargetBuy$23.00 ➝ $30.00
3/4/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Boost Price TargetBuy$27.00 ➝ $29.00
3/4/2026
Transcat, Inc. stock logo
TRNS
Transcat
UpgradeStrong SellHold
2/27/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Boost Price TargetBuy$2.50 ➝ $4.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allient Inc. stock logo
ALNT
Allient
$554.48M2.40$3.80 per share20.57$17.79 per share4.40
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$31.37M36.72N/AN/A$3.70 per share3.72
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/A$1.14 per shareN/A
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.60$4.69 per share16.54$30.82 per share2.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allient Inc. stock logo
ALNT
Allient
$22.03M$1.3259.6526.00N/A3.97%12.53%6.21%5/6/2026 (Confirmed)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.16N/AN/AN/A-739.39%-88.31%-72.52%5/6/2026 (Estimated)
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$59M-$0.46N/AN/AN/AN/A-35.04%-29.16%N/A
Transcat, Inc. stock logo
TRNS
Transcat
$14.52M$0.8591.3041.72N/A2.47%6.15%4.15%5/25/2026 (Estimated)

Latest NAUT, ALNT, EYPT, and TRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/25/2026Q4 2026
Transcat, Inc. stock logo
TRNS
Transcat
$0.5580N/AN/AN/A$89.79 millionN/A
5/6/2026Q1 2026
Allient Inc. stock logo
ALNT
Allient
$0.55N/AN/AN/A$138.42 millionN/A
5/6/2026Q1 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million
4/28/2026Q1 2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.1450-$0.12+$0.0250-$0.12$0.25 millionN/A
3/5/2026Q4 2025
Allient Inc. stock logo
ALNT
Allient
$0.46$0.55+$0.09$0.38$133.33 million$143.35 million
3/4/2026Q4 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.78-$0.8143-$0.0343-$0.81$1.01 million$0.62 million
2/26/2026Q4 2025
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.14-$0.11+$0.03-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Allient Inc. stock logo
ALNT
Allient
$0.120.15%+8.45%9.09%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A

Latest NAUT, ALNT, EYPT, and TRNS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/5/2026
Allient Inc. stock logo
ALNT
Allient
quarterly$0.030.2%3/20/20263/20/20264/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allient Inc. stock logo
ALNT
Allient
0.60
3.66
2.08
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
8.88
8.83
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/A
11.85
11.85
Transcat, Inc. stock logo
TRNS
Transcat
0.34
2.21
1.85

Institutional Ownership

CompanyInstitutional Ownership
Allient Inc. stock logo
ALNT
Allient
61.57%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
50.71%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
Allient Inc. stock logo
ALNT
Allient
15.00%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
41.10%
Transcat, Inc. stock logo
TRNS
Transcat
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allient Inc. stock logo
ALNT
Allient
2,47817.02 million14.47 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12083.79 million80.06 millionOptionable
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
130127.08 million74.85 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
1,2459.33 million9.07 millionOptionable

Recent News About These Companies

Transcat Names Jaime Irick as CEO
Transcat, Inc. (TRNS) Q3 2026 Earnings Call Transcript
Transcat: The Storm Has Passed (Upgrade)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allient stock logo

Allient NASDAQ:ALNT

$78.25 +0.25 (+0.32%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Allient Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, authorized manufacturers' representatives, and distributors. The company was formerly known as Allied Motion Technologies Inc. and changed its name to Allient Inc. in August 2023. Allient Inc. was incorporated in 1962 and is headquartered in Amherst, New York.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$13.75 0.00 (-0.01%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Nautilus Biotechnology stock logo

Nautilus Biotechnology NASDAQ:NAUT

$2.90 +0.04 (+1.40%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Transcat stock logo

Transcat NASDAQ:TRNS

$77.60 +2.28 (+3.02%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.